Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis

Last updated: January 7, 2025
Sponsor: University of Pittsburgh
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatitis

Chronic Pain

Primary Biliary Cholangitis

Treatment

Quantitative Sensory Test 3

Quantitative Sensory Test 2

Quantitative Sensory Test 1

Clinical Study ID

NCT04996628
STUDY21050169
R01DK127042
  • Ages > 18
  • All Genders

Study Summary

Abdominal pain in chronic pancreatitis (CP) affects up to 90% of patients during the course of their disease, and response to currently available therapies is suboptimal and unpredictable. The proposed clinical trial will evaluate the predictive capability of Pancreatic Quantitative Sensory Testing (P-QST) - a novel assessment of neurosensory phenotyping- for improvement in pain in patients with CP who are undergoing medically-indicated invasive treatment with endoscopic therapy or surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients ≥ 18 years of age with definite CP undergoing decompressive invasivetreatments (endoscopic therapy or surgery) to relieve main pancreatic ductobstruction due to stones and/or stricture for management of pain.

  • Endoscopic therapy: Endoscopic Retrograde Cholangiopancreatography (ERCP) withpancreatic duct stone removal, stent placement, and/or stricture dilation, ±intraductal lithotripsy or Extracorporeal Shock Wave Lithotripsy (ESWL).

  • Surgery: drainage procedures (Frey and Puestow operations)

Exclusion

Exclusion Criteria:

  • Patients with chronic pain from conditions other than CP

  • Patients < 18 years of age

  • Patients who have had endoscopic therapy within the past 12 months

  • Patients who have undergone prior pancreatic surgery

  • Patients who have resective surgical procedure planned (eg. Whipple procedure, TotalPancreatectomy)

  • Patients with peripheral sensory deficits

  • Patients with known pregnancy at the time of study screening**

  • Note: Women who become pregnant during the course of the study can no longerparticipate in P-QST testing.

Study Design

Total Participants: 150
Treatment Group(s): 3
Primary Treatment: Quantitative Sensory Test 3
Phase:
Study Start date:
January 04, 2022
Estimated Completion Date:
June 30, 2026

Study Description

P-QST has been shown to be able to phenotype patients with CP into nociceptive patterns according to degree of central sensitization. As a tool to identify baseline nociceptive pattern in patients with painful CP, P-QST will be performed at baseline prior to planned invasive treatment with endoscopic therapy or decompressive surgery. We will evaluate the ability of P-QST to predict response to invasive treatment for painful CP, and to develop a predictive model for individualized prediction of treatment response.

Patients will undergo pre-procedure P-QST testing before undergoing scheduled invasive treatment as directed by their treating gastroenterologist. The date of first endoscopic therapy or surgery will be used to calculate follow-up timepoints, which will be scheduled at 3, 6, and 12 months after the first endotherapy session or surgery. At each follow-up time point, patients will answer questions about their pain. In addition, patients will complete patient reported outcome tools (HADS, PCS instruments) and the Patient Global Impression of Change. Serum and urine samples will be obtained at baseline and at 6-month follow-up timepoints.

Connect with a study center

  • Indiana University Medical Center

    Indianapolis, Indiana 46202
    United States

    Active - Recruiting

  • Johns Hopkins Medical Institutions

    Baltimore, Maryland 21287
    United States

    Active - Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania 15213
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.